ArticleJAMA internal medicine2014
The role of testing for BRCA1 and BRCA2 mutations in cancer prevention.
Article in JAMA internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Willingness to contribute monetarily for hereditary breast cancer risk testing and the influencing factors: The first Indonesian exploration in the province with the highest prevalence.Exploratory research in clinical and social pharmacy · 2026Article
- Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units.Current oncology (Toronto, Ont.) · 2026Article
- From Biobank to Bedside: A Pilot Study on Returning Medically Actionable BRCA1/2 Results in Qatar's Precision Medicine Landscape.Biomedicines · 2025Article
- Early and hereditary breast cancer: advances in risk stratification and imaging approaches.Therapeutic advances in medical oncology · 2025Review
- Genetic screening of FFPE breast cancer biopsies for theRevista panamericana de salud publica = Pan American journal of public health · 2025Article
- Chinese American and Non-Hispanic White Breast Cancer Patients' Knowledge and Use of BRCA Testing.International journal of environmental research and public health · 2023Article
- Review
- Prevalence of Clinically Relevant GermlineFrontiers in genetics · 2022Article
- A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes.Molecular medicine reports · 2018Article
- Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study.Cancer medicine · 2017Article
- Article
- Population genetic testing for cancer susceptibility: founder mutations to genomes.Nature reviews. Clinical oncology · 2016Review
- Walking in the shoes of patients, not just in their genes: a patient-centered approach to genomic medicine.The patient · 2015Article
- New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.BMC medical genomics · 2015Article
- The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine.Hereditary cancer in clinical practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.